Men With mHSPC And Germline Mutations At Higher Risk Of Death Than Those Without Mutations, Study Finds

Renal & Urology News (7/1, Charnow) reports, “Men with metastatic hormone-sensitive prostate cancer (mHSPC) who carry germline mutations are at higher risk for death compared with noncarriers, according to investigators.” Additionally, “carriers of BRCA2 germline mutations are at significantly elevated risk for both progression to castration-resistant prostate cancer (CRPC) and death.” These findings were published in Urologic Oncology: Seminars and Original Investigations.